Phimap is a new joint venture between Mapi Naxis, a scientific leader in late stage clinical trials and pharmaco-epidemiological studies, and Adelphi Group Products, a leader in disease understanding and brand development programmes.

A full-service company, Phimap design, implement and deliver global epidemiology, pharmaco-epidemiology and longitudinal observational studies.

Such real-world studies, pertaining to disease understanding based on epidemiological principles and to the efficacy, safety and optimal use of products are becoming critical in a drug development environment that is ever-more complex and demanding, and where knowledge of the incidence, prevalence and features of the conditions are crucial for both product development and launch.

Phimap operates worldwide, with a flexible structure that offers clients the appropriate framework to conduct studies simultaneously in several countries.

Combined with our experience and expertise in communications, this allows clients to target a wide range of audiences including doctors, registration authorities, reimbursement and pricing authorities.

Phimap is looking to expand its network of freelance CRA to work on a variety of projects. If you are interested in joining us, please click here to complete our registration form.

Click for CRA Registration form